MRNA - Moderna Inc Stock Price, Fair Value and News

103.86USD-1.28 (-1.22%)Market Closed

Market Summary

USD103.86-1.28

Market Closed

-1.22%

MRNA Alerts

2 major insider sales recently.

MRNA Stock Price

View Fullscreen

MRNA RSI Chart

MRNA Valuation

Market Cap

39.7B

Price/Earnings (Trailing)

-8.42

Price/Sales (Trailing)

5.79

EV/EBITDA

-9.42

Price/Free Cashflow

-10.37

MRNA Price/Sales (Trailing)

MRNA Profitability

EBT Margin

-57.56%

Return on Equity

-34.03%

Return on Assets

-25.58%

Free Cashflow Yield

-9.64%

MRNA Fundamentals

MRNA Revenue

Revenue (TTM)

6.8B

Rev. Growth (Yr)

-44.71%

Rev. Growth (Qtr)

53.52%

MRNA Earnings

Earnings (TTM)

-4.7B

Earnings Growth (Yr)

-85.19%

Earnings Growth (Qtr)

105.98%

Breaking Down MRNA Revenue

Last 7 days

-1.2%

Last 30 days

0.0%

Last 90 days

1.7%

Trailing 12 Months

-33.9%

How does MRNA drawdown profile look like?

MRNA Financial Health

Current Ratio

3.42

MRNA Investor Care

Buy Backs (1Y)

1.10%

Diluted EPS (TTM)

-12.37

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	15.1B	10.7B	9.1B	6.8B
2022	22.6B	23.0B	21.4B	19.3B
2021	2.7B	7.0B	11.8B	18.5B
2020	52.2M	106.1M	246.1M	803.0M
2019	122.1M	106.3M	81.6M	60.2M
2018	204.5M	192.3M	191.6M	135.1M
2017	132.8M	157.1M	181.5M	205.8M
2016	0	0	0	108.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Moderna Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 10, 2024	afeyan noubar	sold	-1,606,860	107	-15,000	-
Apr 08, 2024	mock james m	sold	-71,859	101	-705	chief financial officer
Apr 05, 2024	mock james m	acquired	-	-	1,453	chief financial officer
Apr 03, 2024	afeyan noubar	sold	-1,525,270	101	-15,000	-
Mar 27, 2024	afeyan noubar	sold	-1,635,860	109	-15,000	-
Mar 20, 2024	afeyan noubar	sold	-1,535,820	102	-15,000	-
Mar 15, 2024	hoge stephen	sold	-1,547,550	103	-15,000	president
Mar 13, 2024	afeyan noubar	sold	-1,628,030	108	-15,000	-
Mar 08, 2024	klinger shannon thyme	sold	-53,883	99.0509	-544	chief legal officer
Mar 07, 2024	klinger shannon thyme	acquired	-	-	1,138	chief legal officer

Which funds bought or sold MRNA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	Financial Synergies Wealth Advisors, Inc.	reduced	-53.2	-64,874	24,936	-%
Apr 12, 2024	Riverview Trust Co	new	-	18,435	18,435	0.01%
Apr 12, 2024	ARMSTRONG ADVISORY GROUP, INC	unchanged	-	-	21,084	-%
Apr 12, 2024	Pacifica Partners Inc.	reduced	-25.00	887	16,544	0.01%
Apr 12, 2024	APEIRON CAPITAL Ltd	reduced	-77.34	-2,349,570	753,273	0.30%
Apr 12, 2024	BALDWIN BROTHERS LLC/MA	unchanged	-	739	11,082	-%
Apr 12, 2024	First PREMIER Bank	new	-	5,000	5,000	-%
Apr 12, 2024	Neumann Advisory Hong Kong Ltd	unchanged	-	157,000	2,356,000	1.16%
Apr 12, 2024	DNB Asset Management AS	reduced	-16.54	-654,040	5,531,850	0.03%
Apr 12, 2024	Cohen Klingenstein LLC	unchanged	-	14,931	223,776	0.01%

Are Funds Buying or Selling MRNA?

Are funds buying MRNA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MRNA

No. of Funds

MRNA Alerts

2 major insider sales recently.

Unveiling Moderna Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	vanguard group inc	10.20%	39,036,765	SC 13G/A
Feb 13, 2024	vanguard group inc	8.89%	33,906,974	SC 13G/A
Feb 07, 2024	bancel stephane	7.8%	30,384,866	SC 13G/A
Jan 29, 2024	blackrock inc.	6.6%	25,301,057	SC 13G/A
Jan 29, 2024	baillie gifford & co	11.97%	45,654,527	SC 13G/A
Feb 10, 2023	bancel stephane	7.41%	29,151,802	SC 13G/A
Feb 09, 2023	vanguard group inc	7.10%	27,282,173	SC 13G/A
Feb 01, 2023	blackrock inc.	6.8%	26,115,224	SC 13G/A
Jan 19, 2023	baillie gifford & co	11.66%	44,786,746	SC 13G/A
Feb 14, 2022	bancel stephane	7.64%	31,538,184	SC 13G/A

Recent SEC filings of Moderna Inc

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	144	Notice of Insider Sale Intent
Apr 12, 2024	4	Insider Trading
Apr 10, 2024	144	Notice of Insider Sale Intent
Apr 10, 2024	SC 13G/A	Major Ownership Report
Apr 09, 2024	4	Insider Trading
Apr 08, 2024	144	Notice of Insider Sale Intent
Apr 05, 2024	4	Insider Trading
Apr 03, 2024	144	Notice of Insider Sale Intent
Mar 29, 2024	4	Insider Trading
Mar 27, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Moderna Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.42	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.6B	1.8B	-1.06%	-27.57%	-42.25	10.17	76.23%	61.08%
BMRN	17.3B	2.4B	9.12%	-7.56%	103	7.14	15.42%	18.43%
INCY	12.0B	3.7B	-8.48%	-28.30%	20.07	3.25	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.5B	-	-6.46%	74.90%	-6.94	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-9.62%	-0.34%	-13.52	11.95	440.80%	-27.84%
ARWR	3.0B	240.7M	-15.06%	-21.14%	-10.03	12.36	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.41	3.83	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.42	4.56	85.90%	-14.05%
NVAX	576.6M	983.7M	-22.12%	-55.02%	-1.06	0.59	-50.36%	17.16%
CRBP	448.6M	881.7K	-2.13%	345.78%	-10.06	466.16	-77.61%	-5.33%
INO	256.8M	4.9M	2.33%	7.75%	-1.9	52.78	-54.97%	51.72%
IBIO	6.7M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

Moderna Inc News

Latest updates

Moderna Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	53.5%	2,811,000	1,831,000	344,000	1,862,000	5,084,000	3,364,000	4,749,000	6,066,000	7,211,000	4,969,000	4,354,000	1,937,000	571,000	157,000	67,000	8,000	14,055	17,046	13,083	16,025	35,421
Costs and Expenses	-27.0%	2,805,000	3,843,000	2,211,000	2,228,000	3,504,000	2,198,000	2,302,000	1,839,000	1,801,000	1,411,000	1,292,000	671,000	846,000	392,000	189,000	139,000	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	393,027	188,478	139,251	144,611	147,810	156,792	157,666	188,452
S&GA Expenses	6.3%	470,000	442,000	332,000	305,000	375,000	278,000	211,000	268,000	201,000	168,000	121,000	77,000	79,000	48,000	37,000	24,000	26,087	28,173	28,487	27,253	38,023
R&D Expenses	21.2%	1,406,000	1,160,000	1,148,000	1,131,000	1,211,000	820,000	710,000	554,000	648,000	521,000	421,000	401,000	759,000	344,000	152,000	115,000	117,645	119,637	128,305	130,413	150,429
EBITDA Margin	-Infinity%	-0.57*	-	0.11*	0.36*	0.52*	0.64*	0.70*	0.73*	0.73*	0.66*	0.56*	0.25*	-0.88*	-	-	-	-	-	-	-	-
Income Taxes	-108.8%	-147,000	1,672,000	-369,000	-384,000	190,000	174,000	277,000	572,000	542,000	219,000	283,000	39,000	2,000	1,000	-	-	-474	-178	-324	-24.00	168
Earnings Before Taxes	103.6%	70,000	-1,958,000	-1,749,000	-305,000	1,655,000	1,217,000	2,474,000	4,229,000	5,410,000	3,552,000	3,063,000	1,260,000	-271,000	-232,000	-117,000	-124,000	-123,743	-123,393	-135,264	-132,600	-141,258
EBT Margin	-122.8%	-0.58*	-0.26*	0.08*	0.33*	0.50*	0.62*	0.68*	0.72*	0.72*	0.64*	0.54*	0.23*	-	-	-	-	-	-	-	-	-
Net Income	106.0%	217,000	-3,630,000	-1,380,000	79,000	1,465,000	1,043,000	2,197,000	3,657,000	4,868,000	3,333,000	2,780,000	1,221,000	-273,000	-233,000	-117,000	-124,000	-123,269	-123,215	-134,940	-132,576	-141,426
Net Income Margin	-81.2%	-0.69*	-0.38*	0.11*	0.32*	0.43*	0.55*	0.61*	0.65*	0.66*	0.60*	0.50*	0.22*	-	-	-	-	-	-	-	-	-
Free Cashflow	123.1%	402,000	-1,740,000	-1,149,000	-1,338,000	1,570,000	163,000	217,000	2,631,000	3,190,000	3,177,000	4,033,000	2,936,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.3%	18,426	19,450	21,884	24,125	25,858	26,056	26,043	27,609	24,669	20,923	16,153	12,694	7,337	4,651	3,486	2,068	1,589	1,591	1,685	1,806	1,962
Current Assets	-4.4%	10,325	10,799	10,599	12,122	13,431	14,297	13,563	16,350	16,071	13,425	10,969	11,703	6,298	3,577	2,797	1,250	1,129	1,094	1,097	1,141	1,563
Cash Equivalents	-0.9%	2,907	2,932	3,801	3,441	3,205	3,027	2,873	5,048	6,848	5,550	5,603	5,442	2,636	1,506	1,762	392	248	174	152	503	670
Inventory	-58.5%	202	487	715	732	949	2,077	1,921	1,942	1,441	965	643	494	47.00	-	-	-	-	-	-	-	-
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	204	209	213	212
Liabilities	-23.7%	4,572	5,995	4,935	5,262	6,735	8,064	8,058	10,534	10,524	10,799	9,449	8,856	4,776	1,891	539	427	415	339	347	360	432
Current Liabilities	-31.2%	3,015	4,385	3,123	3,499	4,923	6,807	6,812	9,238	9,128	9,957	8,840	8,441	4,389	1,474	162	135	143	148	162	159	223
Shareholder's Equity	3.0%	13,854	13,455	16,949	18,863	19,123	17,992	17,985	17,075	14,145	10,124	6,704	3,838	2,561	2,760	2,947	1,641	1,175	1,248	1,335	1,442	1,530
Retained Earnings	1.6%	13,606	13,389	17,019	18,399	18,320	16,855	15,812	13,615	9,958	5,090	1,757	-1,023	-2,244	-1,970	-1,737	-1,620	-1,496	-1,369	-1,246	-1,111	-1,006
Additional Paid-In Capital	33.9%	371	277	193	731	1,173	1,488	2,413	3,644	4,211	5,003	4,931	4,860	4,802	4,726	4,676	3,268	2,669	2,618	2,582	2,557	2,538
Shares Outstanding	0.3%	382	381	381	384	385	396	399	402	403	402	401	400	-	-	-	-	-	-	-	-	-
Float	-	-	-	40,200	-	-	-	48,800	-	-	-	80,800	-	-	-	25,250	-	-	-	3,380	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	138.9%	622	-1,600	-915	-1,225	1,662	252	304	2,763	3,310	3,276	4,063	2,971	1,264	893	-24.00	-106	-99.05	-107	-108	-144	-91.02
Share Based Compensation	2.6%	79.00	77.00	74.00	75.00	62.00	70.00	50.00	44.00	37.00	40.00	35.00	30.00	26.00	22.00	25.00	20.00	20.00	21.00	21.00	18.00	32.00
Cashflow From Investing	-168.2%	-538	789	1,944	2,011	-1,048	945	-1,152	-3,921	-1,138	-3,327	-3,878	-180	-190	-1,179	13.00	-316	130	113	-246	-11.76	6.00
Cashflow From Financing	-87.9%	-109	-58.00	-668	-542	-438	-1,041	-1,327	-642	-873	-2.00	-24.00	26.00	44.00	30.00	1,381	578	32.00	16.00	4.00	0.00	576
Buy Backs	100.0%	-	-1.00	628	526	402	1,006	1,298	623	857	-	-	-	-	-	-	-	-	-	-	-	-

MRNA Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Total revenue	$ 6,848	$ 19,263	$ 18,471
Operating expenses:
Cost of sales	4,693	5,416	2,617
Research and development	4,845	3,295	1,991
Selling, general and administrative	1,549	1,132	567
Total operating expenses	11,087	9,843	5,175
(Loss) income from operations	(4,239)	9,420	13,296
Interest income	421	200	18
Other expense, net	(124)	(45)	(29)
(Loss) income before income taxes	(3,942)	9,575	13,285
Provision for income taxes	772	1,213	1,083
Net (loss) income	$ (4,714)	$ 8,362	$ 12,202
(Loss) earnings per share:
Basic (in usd per share)	$ (12.33)	$ 21.26	$ 30.31
Diluted (in usd per share)	$ (12.33)	$ 20.12	$ 28.29
Weighted average common shares used in calculation of (loss) earnings per share:
Basic (in shares)	382	394	403
Diluted (in shares)	382	416	431
Net product sales
Revenue:
Total revenue	$ 6,671	$ 18,435	$ 17,675
Other revenue
Revenue:
Total revenue	$ 177	$ 828	$ 796

MRNA Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,907	$ 3,205
Investments	5,697	6,697
Accounts receivable, net	892	1,385
Inventory	202	949
Prepaid expenses and other current assets	627	1,195
Total current assets	10,325	13,431
Investments, non-current	4,677	8,318
Property, plant and equipment, net	1,945	2,018
Right-of-use assets, operating leases	713	121
Deferred tax assets	81	982
Other non-current assets	685	988
Total assets	18,426	25,858
Current liabilities:
Accounts payable	520	487
Accrued liabilities	1,798	2,101
Deferred revenue	568	2,038
Income taxes payable	63	48
Other current liabilities	66	249
Total current liabilities	3,015	4,923
Deferred revenue, non-current	83	673
Operating lease liabilities, non-current	643	92
Financing lease liabilities, non-current	575	912
Other non-current liabilities	256	135
Total liabilities	4,572	6,735
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.0001; 162 shares authorized as of December 31, 2023 and 2022; no shares issued or outstanding at December 31, 2023 and 2022	0	0
Common stock, par value $0.0001; 1,600 shares authorized as of December 31, 2023 and 2022; 382 and 385 shares issued and outstanding as of December 31, 2023 and 2022, respectively	0	0
Additional paid-in capital	371	1,173
Accumulated other comprehensive loss	(123)	(370)
Retained earnings	13,606	18,320
Total stockholders’ equity	13,854	19,123
Total liabilities and stockholders’ equity	$ 18,426	$ 25,858

About Moderna Inc

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration agreement with CARsgen Therapeutics Holdings Limited to evaluate CTO41in combination with mRNA cancer vaccine. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Stephane Bancel
WEBSITE	modernatx.com
INDUSTRY	Biotechnology
EMPLOYEES	3900

Moderna Inc Frequently Asked Questions

What is the ticker symbol for Moderna Inc? What does MRNA stand for in stocks?

MRNA is the stock ticker symbol of Moderna Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Moderna Inc (MRNA)?

As of Mon Apr 15 2024, market cap of Moderna Inc is 39.68 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRNA stock?

You can check MRNA's fair value in chart for subscribers.

What is the fair value of MRNA stock?

You can check MRNA's fair value in chart for subscribers. The fair value of Moderna Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Moderna Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Moderna Inc a good stock to buy?

The fair value guage provides a quick view whether MRNA is over valued or under valued. Whether Moderna Inc is cheap or expensive depends on the assumptions which impact Moderna Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRNA.

What is Moderna Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, MRNA's PE ratio (Price to Earnings) is -8.42 and Price to Sales (PS) ratio is 5.79. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRNA PE ratio will change depending on the future growth rate expectations of investors.